newsfilter
← Latest News
GlobeNewswire·

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments,